NCT02233816View on ClinicalTrials.gov

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 28, 2014

Primary Completion Date

June 22, 2015

Study Completion Date

June 22, 2015

Conditions
Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections
Interventions
BIOLOGICAL

Low dose of quadrivalent VLP vaccine

A single low dose of quadrivalent VLP vaccine

BIOLOGICAL

Medium dose of quadrivalent VLP vaccine

A single medium dose of quadrivalent VLP vaccine

BIOLOGICAL

High dose of quadrivalent VLP vaccine

A single high dose of quadrivalent VLP vaccine

BIOLOGICAL

Placebo

A single dose of placebo

Trial Locations (2)

33024

Broward Research Group, Hollywood

33143

Miami Research Associates, Miami

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT02233816 - Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter